drug protocol number

TMC435HPC3014

drug sponsor

Janssen-Cilag International NV

drug study

TMC435 (simeprevir) / Pegylated interferon alfa-2a (PegIFNα-2a) / Ribavirin (RBV)

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh)_ King Abdulaziz Medical City NG (Riyadh)_ King Khalid University Hospital (Riyadh)

drug status

Completed

drug phase